Emerging immune checkpoints in the tumor microenvironment: Implications for cancer immunotherapy
Author:
Funder
Science and Technology Commission of Shanghai Municipality
National Natural Science Foundation of China
Publisher
Elsevier BV
Subject
Cancer Research,Oncology
Reference125 articles.
1. A decade of immune-checkpoint inhibitors in cancer therapy;Robert;Nat. Commun.,2020
2. Ipilimumab: first global approval;Cameron;Drugs,2011
3. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations;Gong;J. Immunother. Cancer,2018
4. Immuno-oncology drug development goes global;Xin Yu;Nat. Rev. Drug Discov.,2019
5. Harnessing the immune system to improve cancer therapy;Papaioannou;Ann. Transl. Med.,2016
Cited by 39 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Research Progress of PD 1/PD L1 Inhibitors in the Treatment of Urological Tumors;Current Cancer Drug Targets;2024-11
2. Construction of a TAN-associated risk score model with integrated multi-omics data analysis and clinical validation in gastric cancer;Life Sciences;2024-07
3. Profiling of Tumor-Infiltrating Immune Cells and Their Impact on Survival in Glioblastoma Patients Undergoing Immunotherapy with Dendritic Cells;International Journal of Molecular Sciences;2024-05-12
4. A novel anti-LAG-3/TIGIT bispecific antibody exhibits potent anti-tumor efficacy in mouse models as monotherapy or in combination with PD-1 antibody;Scientific Reports;2024-05-09
5. Crosstalk between metabolism and cell death in tumorigenesis;Molecular Cancer;2024-04-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3